Skip to main content
Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. Advani, R. H., Flinn, I., Sharman, J., Diefenbach, C., Kolibaba, K. S., Press, O. W., Sehn, L., Chen, A. I., Salles, G. A., Tilly, H., Cheson, B. D., Assouline, S. E., Dreyling, M. H., Hagenbeek, A., Zinzani, P., Jones, C., Chu, Y., Hirata, J., Wenger, M., Morschhauser, F. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036901816